Drug intelligence / Profile preview

SC717

Development stage: Preclinical
Lead developer: ViroCure
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

SC717 (also known as SquiCure) is an oncolytic virus therapy being developed by the South Korean biotechnology company ViroCure. The therapy utilizes a naturally occurring, squirrel-specific poxvirus (isolated from grey squirrels) that has been patented for its ability to selectively infect and destroy cancer cells. Preclinical studies have demonstrated the virus's potential in treating animal tumors, and ViroCure claims the virus is non-toxic to humans. While it serves as a foundational platform for the company's poxvirus pipeline, specific clinical development for SC717 as a standalone human therapeutic is in the early stages, with the virus primarily serving as a platform for further engineering.

Brand names: SquiCure
Other names: squirrel-specific poxvirusgrey squirrel poxvirus

Beyond the preview

Go deeper on SC717.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SC717.

Explore the full profile